Co-pay Programs in the Crosshairs: An Evidence-based Response to Critics

Co-pay Programs in the Crosshairs: An Evidence-based Response to Critics

Click here to register

Date:
Wednesday, December 4
Time: 11:00 a.m. PT/ 2:00 p.m. ET

We've heard the continuous drumbeat from payers and PBMs: “Co-pay programs interfere with generic substitution!” “They subvert cost-sharing ‘strategies' that payers put in place!” “They increase health care costs!” That's what they say, but what's the real truth? This presentation uses payers' own data to uncover the surprising evidence supporting co-pay offset programs.

Featured Speakers:
Chris Dowd, Senior Vice President of Market and Product Development, PSKW

E.M. (Mick) Kolassa, MBA, PhD – Founding Partner, Medical Marketing Economics

Sponsored by:

You must be a registered member of MMM to post a comment.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.